» Articles » PMID: 31339341

Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population

Overview
Publisher Sage Publications
Date 2019 Jul 25
PMID 31339341
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Previous studies have shown that adherence to low-dose aspirin (LDA) is suboptimal. However, these studies were based on an average measure of adherence during follow-up, ignoring its dynamic process over time. We described the trajectories of adherence to LDA treatment among the French population over 3 years of follow-up.

Methods: We identified a cohort of 11 793 new LDA users, aged ≥50 years in 2010, by using the French national health-care database. Patients included had at least 3 years of history in the database before study entry to exclude prevalent aspirin users and to assess baseline comorbidities. They were followed from the first date of LDA supply (the index date) until the first date among death, exit from the database, or 3 years after the index date. Adherence to LDA was assessed every 3 months by using the proportion of days covered (PDC) and dichotomized with a cutoff of PDC of 0.8. We used group-based trajectory modeling to identify trajectories of LDA adherence. Predictors of LDA adherence trajectory membership were identified by multinomial logistics regression.

Results: We identified 4 trajectories of adherence among new LDA users: the not-adherents (4737 [40.2%]), the delayed not-adherents (gradual decrease in adherence probability, 1601 [13.6%]), the delayed adherents (gradual increase in adherence probability, 1137 [9.6%]), and the persistent adherents (4318 [36.6%]). The probability of belonging to the not-adherent group was increased with female sex, low socioeconomic status, and polymedication and was reduced with a secondary indication for LDA use, such as diabetes, hypertension, and dementia, at least 4 consultations in the previous year, or 1 hospitalization or a cardiologist consultation in the 3 months before the index date.

Conclusion: This study provides a dynamic picture of adherence behaviors among new LDA users and underlines the presence of critical trajectories that intervention could target to improve adherence.

Citing Articles

Longitudinal Trajectory Modeling to Assess Adherence to Sacubitril/Valsartan among Patients with Heart Failure.

Mucherino S, Dima A, Coscioni E, Vassallo M, Orlando V, Menditto E Pharmaceutics. 2023; 15(11).

PMID: 38004547 PMC: 10674925. DOI: 10.3390/pharmaceutics15112568.


Long-Term Adherence and Persistence to Low-Dose Aspirin for the Prevention of Cardiovascular Disease: A Population-Based Cohort Study.

Vora P, Soriano-Gabarro M, Russell B, Morgan Stewart H Int J Clin Pract. 2022; 2022:7786174.

PMID: 36540065 PMC: 9734008. DOI: 10.1155/2022/7786174.


What methods are used to study the association between medication adherence trajectories, estimated with the group-based trajectory modeling (GBTM) method, and health-related outcomes?-a protocol for a systematic review.

Memoli V, Ekanmian G, Lunghi C, Bouhnik A, Lauzier S, Guenette L Syst Rev. 2022; 11(1):102.

PMID: 35610710 PMC: 9128283. DOI: 10.1186/s13643-022-01971-y.


Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS.

Dalli L, Kilkenny M, Arnet I, Sanfilippo F, Cummings D, Kapral M Br J Clin Pharmacol. 2022; 88(10):4427-4442.

PMID: 35524398 PMC: 9546055. DOI: 10.1111/bcp.15391.


Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries.

Hawley C, Lauffenburger J, Paik J, Wexler D, Kim S, Patorno E Diabetes Care. 2022; 45(3):604-613.

PMID: 35043165 PMC: 8918201. DOI: 10.2337/dc21-1676.